Clinical Trial Update: A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Debio 025 (alisporivir) in combination with pegylated interferon alfa-2a and ribavirin in chronic hepatitis C patients who did not re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Debio 025 (alisporivir)
• PegIFN Alpha-2a (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Debiopharm International SA | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2015-05-07